{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T13:19:31Z","timestamp":1779887971026,"version":"3.53.1"},"reference-count":79,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["bprch.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Haematology"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.beha.2015.09.003","type":"journal-article","created":{"date-parts":[[2015,10,20]],"date-time":"2015-10-20T00:39:53Z","timestamp":1445301593000},"page":"236-245","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Immunoconjugates in the management of hairy cell leukemia"],"prefix":"10.1016","volume":"28","author":[{"given":"Robert J.","family":"Kreitman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira","family":"Pastan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2015.09.003_bib1","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1182\/blood.V13.7.609.609","article-title":"Leukemic reticuloendotheliosis","volume":"13","author":"Bouroncle","year":"1958","journal-title":"Blood"},{"issue":"65","key":"10.1016\/j.beha.2015.09.003_bib2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3322\/caac.21254","article-title":"Cancer statistics","volume":"2015","author":"Siegel","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.beha.2015.09.003_bib3","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1200\/JCO.1995.13.4.974","article-title":"Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study","volume":"13","author":"Grever","year":"1995","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2015.09.003_bib4","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","volume":"2","author":"Swerdlow","year":"2008"},{"key":"10.1016\/j.beha.2015.09.003_bib5","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S1521-6926(02)00086-5","article-title":"The variant form of hairy-cell leukaemia","volume":"16","author":"Matutes","year":"2003","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.beha.2015.09.003_bib6","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/0145-2126(80)90066-1","article-title":"A\u00a0chronic lymphoproliferative disorder with distinctive features: a distinct variant of hairy-cell leukaemia","volume":"4","author":"Cawley","year":"1980","journal-title":"Leuk Res"},{"key":"10.1016\/j.beha.2015.09.003_bib7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ctrv.2010.05.003","article-title":"Hairy-cell leukemia variant: recent view on diagnosis, biology and treatment","volume":"37","author":"Robak","year":"2011","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.beha.2015.09.003_bib8","author":"Shao","year":"2015","journal-title":"JBB"},{"key":"10.1016\/j.beha.2015.09.003_bib9","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.hoc.2006.06.012","article-title":"Immunophenotyping and differential diagnosis of hairy cell leukemia","volume":"20","author":"Matutes","year":"2006","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.beha.2015.09.003_bib10","author":"Venkataraman","year":"2015","journal-title":"JBB"},{"key":"10.1016\/j.beha.2015.09.003_bib11","author":"Jasper","year":"2015","journal-title":"JBB"},{"key":"10.1016\/j.beha.2015.09.003_bib12","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.hoc.2006.06.010","article-title":"Hairy cell leukemia: diagnostic pathology","volume":"20","author":"Sharpe","year":"2006","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.beha.2015.09.003_bib13","author":"Arons","year":"2015","journal-title":"JBB"},{"key":"10.1016\/j.beha.2015.09.003_bib14","author":"Xi","year":"2015","journal-title":"JBB"},{"key":"10.1016\/j.beha.2015.09.003_bib15","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1182\/blood.V92.6.1918","article-title":"Long-term follow-up of patients with hairy cell leukemia after cladribine treatment","volume":"92","author":"Saven","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.beha.2015.09.003_bib16","author":"Kreitman","year":"2015","journal-title":"JBB"},{"key":"10.1016\/j.beha.2015.09.003_bib17","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1182\/blood-2005-01-0173","article-title":"Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern university experience","volume":"106","author":"Chadha","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.beha.2015.09.003_bib18","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJM199004193221605","article-title":"Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine","volume":"322","author":"Piro","year":"1990","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beha.2015.09.003_bib19","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1056\/NEJM198704023161401","article-title":"Remissions in hairy-cell leukemia with pentostatin (2\u02b9-deoxycoformycin)","volume":"316","author":"Spiers","year":"1987","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beha.2015.09.003_bib20","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1200\/JCO.2003.05.093","article-title":"Extended follow-up of patients with hairy cell leukemia after treatment with cladribine","volume":"21","author":"Goodman","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2015.09.003_bib21","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1365-2141.2009.07668.x","article-title":"Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis","volume":"145","author":"Else","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2015.09.003_bib22","first-page":"2981","article-title":"Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin","volume":"96","author":"Flinn","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.beha.2015.09.003_bib23","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1182\/blood-2013-06-508754","article-title":"Clinical characteristics and long-term outcome of young hairy cell leukemia patients treated with cladribine: a single-institution series","volume":"123","author":"Rosenberg","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.beha.2015.09.003_bib24","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/(SICI)1097-4547(19980115)51:2<162::AID-JNR5>3.0.CO;2-B","article-title":"Autonomic neuropathy in transgenic mice caused by immunotoxin targeting of the peripheral nervous system","volume":"51","author":"Sawada","year":"1998","journal-title":"J\u00a0Neurosci Res"},{"key":"10.1016\/j.beha.2015.09.003_bib25","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S1521-6926(02)00089-0","article-title":"Cladribine in the treatment of hairy-cell leukaemia","volume":"16","author":"Goodman","year":"2003","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.beha.2015.09.003_bib26","first-page":"405","article-title":"Consensus resolution: proposed criteria for evaluation of response to treatment in hairy cell leukemia","volume":"1","year":"1987","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2015.09.003_bib27","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1200\/JCO.1998.16.9.3007","article-title":"Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the group C protocol mechanism of the National Cancer Institute: a report of 979 patients","volume":"16","author":"Cheson","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2015.09.003_bib28","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1182\/blood.V94.10.3340.422k19_3340_3348","article-title":"Responses in refractory hairy cell leukemia to a recombinant immunotoxin","volume":"94","author":"Kreitman","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.beha.2015.09.003_bib29","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1200\/JCO.2000.18.8.1622","article-title":"Phase I trial of recombinant immunotoxin Anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies","volume":"18","author":"Kreitman","year":"2000","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2015.09.003_bib30","doi-asserted-by":"crossref","first-page":"6719","DOI":"10.1200\/JCO.2005.11.437","article-title":"Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies","volume":"23","author":"Kreitman","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2015.09.003_bib31","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1200\/JCO.2008.20.2630","article-title":"Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia","volume":"27","author":"Kreitman","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2015.09.003_bib32","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1200\/JCO.2011.38.1756","article-title":"Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia","volume":"30","author":"Kreitman","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2015.09.003_bib33","doi-asserted-by":"crossref","first-page":"6873","DOI":"10.1158\/1078-0432.CCR-13-1752","article-title":"Cladribine with immediate rituximab for the treatment of patients with variant hairy cell leukemia","volume":"19","author":"Kreitman","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.beha.2015.09.003_bib34","doi-asserted-by":"crossref","first-page":"6313","DOI":"10.1158\/1078-0432.CCR-13-1848","article-title":"Bendamustine and rituximab in relapsed and refractory hairy cell leukemia","volume":"19","author":"Burotto","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.beha.2015.09.003_bib35","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1158\/1078-0432.CCR-05-2315","article-title":"Minimal residual disease in hairy cell leukemia patients assessed by clone-specific polymerase chain reaction","volume":"12","author":"Arons","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.beha.2015.09.003_bib36","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1172\/JCI111516","article-title":"Pseudomonas exotoxin-Anti-Tac: cell specific immunotoxin active against cells expressing the human T cell growth factor receptor","volume":"74","author":"FitzGerald","year":"1984","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.beha.2015.09.003_bib37","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1182\/blood.V65.6.1416.bloodjournal6561416","article-title":"Adult T cell leukemia: a potential target for ricin A chain immunotoxins","volume":"65","author":"Kronke","year":"1985","journal-title":"Blood"},{"key":"10.1016\/j.beha.2015.09.003_bib38","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/0092-8674(86)90506-4","article-title":"Immunotoxins","volume":"47","author":"Pastan","year":"1986","journal-title":"Cell"},{"key":"10.1016\/j.beha.2015.09.003_bib39","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/0092-8674(78)90099-5","article-title":"One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell","volume":"15","author":"Yamaizumi","year":"1978","journal-title":"Cell"},{"key":"10.1016\/j.beha.2015.09.003_bib40","doi-asserted-by":"crossref","first-page":"5908","DOI":"10.1016\/S0021-9258(18)45660-8","article-title":"The mechanism of action of ricin and related toxic lectins on eukaryotic ribosomes","volume":"262","author":"Endo","year":"1987","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.beha.2015.09.003_bib41","doi-asserted-by":"crossref","first-page":"8707","DOI":"10.1016\/S0021-9258(18)47472-8","article-title":"Active site of Pseudomonas aeruginosa exotoxin A. Glutamic acid 553 is photolabeled by NAD and shows functional homology with glutamic acid 148 of diphtheria toxin","volume":"262","author":"Carroll","year":"1987","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.beha.2015.09.003_bib42","article-title":"ADP-ribosylation of elongation factor 2 by diphtheria toxin. Isolation and properties of the novel ribosyl-amino acid and its hydrolysis products","volume":"255","author":"Van Ness","year":"1980","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.beha.2015.09.003_bib43","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1073\/pnas.85.6.1922","article-title":"Cytotoxic activity of an interleukin 2-Pseudomonas exotoxin chimeric protein produced in Escherichia coli","volume":"85","author":"Lorberboum-Galski","year":"1988","journal-title":"Proc Natl Acad Sci U. S. A"},{"key":"10.1016\/j.beha.2015.09.003_bib44","doi-asserted-by":"crossref","first-page":"21118","DOI":"10.1016\/S0021-9258(18)54828-6","article-title":"Cytotoxic properties of DAB486EGF and DAB389EGF, epidermal growth factor (EGF) receptor-targeted fusion toxins","volume":"266","author":"Shaw","year":"1991","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.beha.2015.09.003_bib45","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S0145-2126(97)00083-0","article-title":"Getting plant toxins to fuse","volume":"21","author":"Kreitman","year":"1997","journal-title":"Leuk Res"},{"key":"10.1016\/j.beha.2015.09.003_bib46","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/339394a0","article-title":"A\u00a0recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin","volume":"339","author":"Chaudhary","year":"1989","journal-title":"Nature"},{"key":"10.1016\/j.beha.2015.09.003_bib47","doi-asserted-by":"crossref","first-page":"6300","DOI":"10.1158\/0008-5472.CAN-08-0461","article-title":"Differential cellular internalization of anti-CD19 and-CD22 immunotoxins results in different cytotoxic activity","volume":"68","author":"Du","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.beha.2015.09.003_bib48","doi-asserted-by":"crossref","first-page":"25396","DOI":"10.1016\/S0021-9258(19)74054-X","article-title":"Cell-mediated cleavage of Pseudomonas exotoxin between Arg279 and Gly280 generates the enzymatically active fragment which translocates to the cytosol","volume":"267","author":"Ogata","year":"1992","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.beha.2015.09.003_bib49","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1128\/IAI.60.2.497-502.1992","article-title":"Characterization of a cellular protease that cleaves Pseudomonas exotoxin","volume":"60","author":"Fryling","year":"1992","journal-title":"Infect Immun"},{"key":"10.1016\/j.beha.2015.09.003_bib50","doi-asserted-by":"crossref","first-page":"18167","DOI":"10.1016\/S0021-9258(17)32431-6","article-title":"Cleavage of Pseudomonas exotoxin and diphtheria toxin by a furin-like enzyme prepared from beef liver","volume":"269","author":"Chiron","year":"1994","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.beha.2015.09.003_bib51","doi-asserted-by":"crossref","first-page":"16507","DOI":"10.1021\/bi991308+","article-title":"Reduction of furin-nicked Pseudomonas exotoxin A: an unfolding story","volume":"38","author":"McKee","year":"1999","journal-title":"Biochemistry"},{"key":"10.1016\/j.beha.2015.09.003_bib52","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1042\/bj3070029","article-title":"Importance of the glutamate residue of KDEL in increasing the cytotoxicity of Pseudomonas exotoxin derivatives and for increased binding to the KDEL receptor","volume":"307","author":"Kreitman","year":"1995","journal-title":"Biochem J"},{"key":"10.1016\/j.beha.2015.09.003_bib53","doi-asserted-by":"crossref","first-page":"5894","DOI":"10.1021\/bi00185a029","article-title":"Domain II of Pseudomonas exotoxin A arrests the transfer of translocating nascent chains into mammalian microsomes","volume":"33","author":"Theuer","year":"1994","journal-title":"Biochemistry"},{"key":"10.1016\/j.beha.2015.09.003_bib54","doi-asserted-by":"crossref","first-page":"7774","DOI":"10.1073\/pnas.90.16.7774","article-title":"The N-terminal region of the 37-kDa translocated fragment of Pseudomonas exotoxin A aborts translocation by promoting its own export after microsomal membrane insertion","volume":"90","author":"Theuer","year":"1993","journal-title":"Proc Natl Acad Sci U. S. A."},{"key":"10.1016\/j.beha.2015.09.003_bib55","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1242\/jcs.035550","article-title":"Diphthamide modification of eEF2 requires a J-domain protein and is essential for normal development","volume":"121","author":"Webb","year":"2008","journal-title":"J\u00a0Cell Sci"},{"key":"10.1016\/j.beha.2015.09.003_bib56","doi-asserted-by":"crossref","first-page":"10427","DOI":"10.1073\/pnas.92.22.10427","article-title":"Cloning and characterization of a cellular apoptosis susceptibility gene, the human homologue to the yeast chromosome segregation gene CSE1","volume":"92","author":"Brinkmann","year":"1995","journal-title":"Proc Natl Acad Sci U. S. A."},{"key":"10.1016\/j.beha.2015.09.003_bib57","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/1097-0215(20000701)87:1<86::AID-IJC13>3.0.CO;2-I","article-title":"Apoptosis induced by immunotoxins used in the treatment of hematologic malignancies","volume":"87","author":"Keppler-Hafkemeyer","year":"2000","journal-title":"Int J Cancer"},{"key":"10.1016\/j.beha.2015.09.003_bib58","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1182\/blood-2003-04-1317","article-title":"Induction of caspase-dependent programmed cell death in B-cell chronic lymphocytic leukemia cells by anti-CD22 immunotoxins","volume":"103","author":"Decker","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.beha.2015.09.003_bib59","doi-asserted-by":"crossref","first-page":"3444","DOI":"10.1128\/MCB.00813-09","article-title":"Pseudomonas exotoxin A-mediated apoptosis is Bak dependent and preceded by the degradation of Mcl-1","volume":"30","author":"Du","year":"2010","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.beha.2015.09.003_bib60","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1021\/bc00020a002","article-title":"Single-chain immunotoxin fusions between anti-Tac and Pseudomonas exotoxin: relative importance of the two toxin disulfide bonds","volume":"4","author":"Kreitman","year":"1993","journal-title":"Bioconj Chem"},{"key":"10.1016\/j.beha.2015.09.003_bib61","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1182\/blood.V80.9.2344.2344","article-title":"Recombinant toxins containing the variable domains of the anti-Tac monoclonal antibody to the interleukin-2 receptor kill malignant cells from patients with chronic lymphocytic leukemia","volume":"80","author":"Kreitman","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.beha.2015.09.003_bib62","first-page":"553","article-title":"Cytotoxic activities of recombinant immunotoxins composed of Pseudomonas toxin or diphtheria toxin toward lymphocytes from patients with adult T-cell leukemia","volume":"7","author":"Kreitman","year":"1993","journal-title":"Leukemia"},{"key":"10.1016\/j.beha.2015.09.003_bib63","first-page":"1059","article-title":"Cytotoxicity of recombinant Fab and Fv immunotoxins on adult T-cell leukemia lymph node and blood cells in the presence of soluble interleukin-2 receptor","volume":"54","author":"Saito","year":"1994","journal-title":"Cancer Res"},{"key":"10.1016\/j.beha.2015.09.003_bib64","first-page":"693","article-title":"Hairy cell leukemia, a B-cell neoplasm which is particularly sensitive to the cytotoxic effect of anti-Tac(Fv)-PE38 (LMB-2)","volume":"6","author":"Robbins","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.beha.2015.09.003_bib65","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1136\/jcp.48.10.955","article-title":"Diagnostic relevance of peripheral blood immunocytochemistry in hairy cell leukaemia","volume":"48","author":"Cordone","year":"1995","journal-title":"J\u00a0Clin Pathol"},{"key":"10.1016\/j.beha.2015.09.003_bib66","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1182\/blood.V82.4.1277.1277","article-title":"Diagnostic application of two-color flow cytometry in 161 cases of hairy cell leukemia","volume":"82","author":"Robbins","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.beha.2015.09.003_bib67","first-page":"819","article-title":"Pseudomonas exotoxin-based immunotoxins containing the antibody LL2 or LL2-Fab' induce regression of subcutaneous human B-cell lymphoma in mice","volume":"53","author":"Kreitman","year":"1993","journal-title":"Cancer Res"},{"key":"10.1016\/j.beha.2015.09.003_bib68","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1021\/bc960043y","article-title":"Characterization of RFB4-Pseudomonas exotoxin A immunotoxins targeted to CD22 on B-cell malignancies","volume":"7","author":"Mansfield","year":"1996","journal-title":"Bioconj Chem"},{"key":"10.1016\/j.beha.2015.09.003_bib69","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1042\/bst0250709","article-title":"Recombinant RFB4 single-chain immunotoxin that is cytotoxic towards CD22-positive cells","volume":"25","author":"Mansfield","year":"1997","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.beha.2015.09.003_bib70","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1182\/blood.V90.5.2020","article-title":"Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors","volume":"90","author":"Mansfield","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.beha.2015.09.003_bib71","doi-asserted-by":"crossref","first-page":"5451","DOI":"10.1021\/bi00184a014","article-title":"Stabilization of the Fv fragments in recombinant immunotoxins by disulfide bonds engineered into conserved framework regions","volume":"33","author":"Reiter","year":"1994","journal-title":"Biochemistry"},{"key":"10.1016\/j.beha.2015.09.003_bib72","first-page":"1476","article-title":"Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) towards fresh malignant cells from patients with B-cell leukemias","volume":"6","author":"Kreitman","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.beha.2015.09.003_bib73","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/(SICI)1097-0215(19990331)81:1<148::AID-IJC24>3.0.CO;2-L","article-title":"Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by cynomolgus monkeys","volume":"81","author":"Kreitman","year":"1999","journal-title":"Int J Cancer"},{"key":"10.1016\/j.beha.2015.09.003_bib74","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0162-3109(97)00041-6","article-title":"Vascular leak syndrome: a side effect of immunotherapy","volume":"37","author":"Baluna","year":"1997","journal-title":"Immunopharmacology"},{"key":"10.1016\/j.beha.2015.09.003_bib75","first-page":"995","article-title":"Improved cytotoxic activity towards cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display","volume":"8","author":"Salvatore","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.beha.2015.09.003_bib76","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1158\/1078-0432.CCR-08-1456","article-title":"CAT-8015: a second-generation pseudomonas exotoxin A-based immunotherapy targeting CD22-expressing hematologic malignancies","volume":"15","author":"Alderson","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.beha.2015.09.003_bib77","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.leukres.2014.06.014","article-title":"An improved recombinant Fab-immunotoxin targeting CD22 expressing malignancies","volume":"38","author":"Bera","year":"2014","journal-title":"Leuk Res"},{"key":"10.1016\/j.beha.2015.09.003_bib78","doi-asserted-by":"crossref","first-page":"8571","DOI":"10.1073\/pnas.1405153111","article-title":"Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes","volume":"111","author":"Mazor","year":"2014","journal-title":"Proc Natl Acad Sci U. S. A."},{"key":"10.1016\/j.beha.2015.09.003_bib79","doi-asserted-by":"crossref","first-page":"14577","DOI":"10.1021\/bi971447w","article-title":"An early step in Pseudomonas exotoxin action is removal of the terminal lysine residue, which allows binding to the KDEL receptor","volume":"36","author":"Hessler","year":"1997","journal-title":"Biochemistry"}],"container-title":["Best Practice &amp; Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692615000158?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692615000158?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T17:30:43Z","timestamp":1653327043000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692615000158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":79,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S1521692615000158"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2015.09.003","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunoconjugates in the management of hairy cell leukemia","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2015.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}